PMID- 28337644
OWN - NLM
STAT- MEDLINE
DCOM- 20170817
LR  - 20240324
IS  - 1534-6293 (Electronic)
IS  - 1528-4042 (Print)
IS  - 1528-4042 (Linking)
VI  - 17
IP  - 4
DP  - 2017 Apr
TI  - CNS Demyelination with TNF-alpha Blockers.
PG  - 36
LID - 10.1007/s11910-017-0742-1 [doi]
LID - 36
AB  - Tumor necrosis factor-alpha (TNF-alpha) blockers are a popular therapeutic choice in a 
      number of inflammatory diseases. Thus far, five TNF- alpha blockers have been 
      approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and 
      certolizumab). Despite being considered relatively safe, serious side effects 
      associated with immune suppression have been reported, including central and 
      peripheral nervous system (CNS) demyelinating disorders. It is still elusive 
      whether these events are mere coincidence or a side effect of anti-TNF-alpha use. In 
      this paper, we review the published case reports of CNS demyelination associated 
      with anti-TNF-alpha therapy and present the follow-up of our 4 previously reported 
      patients who developed neurologic symptoms suggestive of CNS demyelination after 
      having received anti-TNF-alpha treatment. We also discuss the possible role of TNF-alpha 
      blockers in demyelination.
FAU - Kemanetzoglou, Elissavet
AU  - Kemanetzoglou E
AD  - Department of Neurology, Agii Anargiri General Oncological Hospital of Kifissia, 
      Athens, Greece.
AD  - 1st Department of Neurology, Athens National and Kapodistrian University, 
      Aeginition Hospital, 74, Vas. Sophia's Ave, Athens, Greece.
FAU - Andreadou, Elisabeth
AU  - Andreadou E
AD  - 1st Department of Neurology, Athens National and Kapodistrian University, 
      Aeginition Hospital, 74, Vas. Sophia's Ave, Athens, Greece. eandread@med.uoa.gr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Neurol Neurosci Rep
JT  - Current neurology and neuroscience reports
JID - 100931790
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Demyelinating Diseases/*drug therapy
MH  - Humans
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC5364240
OTO - NOTNLM
OT  - Anti-TNF-alpha
OT  - Demyelination
OT  - Multiple sclerosis
OT  - Tumor necrosis factor
COIS- CONFLICT OF INTEREST: Elissavet Kemanetzoglou and Elisabeth Andreadou declare 
      that they have no conflict of interest. HUMAN AND ANIMAL RIGHTS AND INFORMED 
      CONSENT: This article does not contain any studies with human or animal subjects 
      performed by any of the authors.
EDAT- 2017/03/25 06:00
MHDA- 2017/08/18 06:00
PMCR- 2017/03/21
CRDT- 2017/03/25 06:00
PHST- 2017/03/25 06:00 [entrez]
PHST- 2017/03/25 06:00 [pubmed]
PHST- 2017/08/18 06:00 [medline]
PHST- 2017/03/21 00:00 [pmc-release]
AID - 10.1007/s11910-017-0742-1 [pii]
AID - 742 [pii]
AID - 10.1007/s11910-017-0742-1 [doi]
PST - ppublish
SO  - Curr Neurol Neurosci Rep. 2017 Apr;17(4):36. doi: 10.1007/s11910-017-0742-1.